• Seagen's Tukysa label expanded; ADARx gets $46M script for RNA trial

    11 days ago - By San Diego Biotechnology

    Seagen just scored another approval for one of its lead drugs. Tukysa won accelerated approval from the FDA on Thursday to be used in combination with Roche's Herceptin for patients with a specific type of...
    Read more ...